Du 2003 (CPZ).

Methods	Allocation: randomised ‐ no further details. Blindness: not reported. Duration: 12 weeks.
Participants	Diagnosis: schizophrenia (CCMD‐2‐R). N=81. Sex: male and female. Age: 18 to 45 years. Excluded: organic psychotic patients; allergic to experiment drugs; with severe physical illness; pregnant or breast feeding women.
Interventions	1. Clozapine: dose not reported. N=32. 2. Chlorpromazine: dose not reported. N=28. 3. Risperidone: dose not reported. N=21
Outcomes	Leaving the study early. Unable to use ‐ Mental state: BPRS (group numbers not reported). Global state: GAS (group numbers not reported). Adverse events: TESS (group numbers not reported).
Notes	CSG: 8466
Risk of bias
Bias	Authors' judgement	Support for judgement
Adequate sequence generation?	Unclear risk	Randomised ‐ no further details
Allocation concealment?	Unclear risk	No details
Blinding? All outcomes	Unclear risk	Not reported
Incomplete outcome data addressed? All outcomes	Low risk	Study attrition reported
Free of selective reporting?	Unclear risk	No details
Free of other bias?	Unclear risk	Unclear